Veltassa Plv 16.8G (Patiromer Others) 16.8G

Veltassa Plv 16.8G contains patiromer for potassium binder use. This oral powder packet helps manage high potassium levels safely. Store at 2–8°C; suitable for short-term therapy. Ideal for patients needing potassium management support.

Strength

16.8G

Pack Size

30s

Storage

2-8°

Manufacturer / TM Owner

VIFOR FRESENIUS MEDICAL

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Patiromer is a potassium binder prescribed to lower high potassium levels in the blood. It works by binding excess potassium in the digestive tract for removal. Commonly used alongside other treatments for potassium control. Often considered when dietary changes alone are insufficient.

Side Effects

This medication helps balance potassium levels without absorbing into the bloodstream. Users may notice improved regularity and reduced potassium-related symptoms over time. Effects vary by individual and treatment duration.

Precautions & Warnings

Keep this medication refrigerated between 2–8°C to maintain potency. Do not freeze or expose to heat. Always take as directed by a healthcare provider. Report any unusual symptoms or side effects promptly.

Avoid Interactions

Patiromer may interact with medications that require stomach acid for absorption, such as certain antibiotics or thyroid drugs. Allow several hours between doses of interacting medicines. Consult a healthcare professional before combining with other treatments.

Frequently Asked Questions

Patiromer is used to lower high potassium levels in the blood.

Mix the powder with water as directed and take it with meals.

Constipation is a reported side effect of patiromer use.

Effects on potassium levels may be seen within hours to days of starting treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.